Topic: Myasthenia Gravis

Myasthenia Gravis

Sep 2021 | Assessment

Myasthenia gravis is a rare chronic autoimmune disorder in which the immune system produces antibodies that prevent acetylcholine from binding with acetylcholine receptors, ultimately resulting in muscle contraction. Interventions of Interest: Efgartigimod (Argenx, Halozyme Therapeutics, and Zai Lab) Eculizumab (Soliris®, Alexion Pharmaceuticals, Inc.)  For more information, please contact Maggie O’Grady, Program Manager, at mogrady@icer.org. View the […]